

Rigosertib

Catalog No: tcsc1710



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

592542-59-1

Formula:

$C_{21}H_{25}NO_8S$

Pathway:

Cell Cycle/DNA Damage

Target:

Polo-like Kinase (PLK)

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

ON-01910

Observed Molecular Weight:

451.49


Product Description

Rigosertib is a non-ATP-competitive inhibitor of **PLK1** with an **IC₅₀** of 9 nM, and shows 30-fold greater selectivity against PLK2.

IC50 & Target: IC50: 9 nM (PLK1), 260 nM (PLK2)^[1]

In Vitro: Rigosertib is non-ATP-competitive inhibitor of PLK1 with IC₅₀ of 9 nM. Rigosertib also exhibits inhibition of PLK2, PDGFR, Flt1, BCR-ABL, Fyn, Src, and CDK1, with IC₅₀ of 18-260 nM. Rigosertib shows cell killing activity against 94 different tumor cell lines with IC₅₀ of 50-250 nM, including BT27, MCF-7, DU145, PC3, U87, A549, H187, RF1, HCT15, SW480, and KB cells. While in normal cells, such as HFL, PrEC, HMEC, and HUVEC, Rigosertib has little or no effect unless its concentration is greater than 5-10 μM. In HeLa cells, Rigosertib (100-250 nM) induces spindle abnormalities and apoptosis^[1]. Rigosertib also inhibits several multidrug resistant tumor cell lines, including MES-SA, MES-SA/DX5a, CEM, and CEM/C2a, with IC₅₀ of 50-100 nM. In DU145 cells, Rigosertib (0.25-5 μM) blocks cell cycle progression in G2/M phase, results in an accumulation of cells containing subG1 content of DNA, and activates apoptotic pathways. In A549 cells, Rigosertib (50 nM-0.5 μM) induces loss of viability and caspase 3/7 activation^[2]. Rigosertib sodium (2 μM) induces apoptosis in chronic lymphocytic leukemia (CLL) cells without toxicity against T-cells or normal B-cells. Rigosertib sodium (2 μM) also abrogates the pro-survival effect of follicular dendritic cells on CLL cells and reduces SDF-1-induced migration of leukemic cells^[3].

In Vivo: Rigosertib (250 mg/kg, i.p.) markedly inhibits tumor growth in mouse xenograft models of Bel-7402, MCF-7, and MIA-PaCa cells^[1]. Rigosertib (200 mg/kg, i.p.) shows inhibition on tumor growth in a mouse xenograft model of BT20 cells^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!